Biosyent Inc (TSXV:RX)
C$ 11 -0.15 (-1.35%) Market Cap: 127.46 Mil Enterprise Value: 111.19 Mil PE Ratio: 18.36 PB Ratio: 3.60 GF Score: 96/100

Q2 2020 Biosyent Inc Earnings Call Transcript

Aug 26, 2020 / NTS GMT
Release Date Price: C$6.7 (-2.62%)
RenÃ;C. Goehrum
BioSyent Inc. - Chairman, CEO & President

© -

Hello, and welcome to the BioSyent Inc. Q2 and First Half 2020 Results Presentation. My name is René Goehrum , and I'm the President and CEO of the company. After drawing your attention to our forward-looking statements disclaimer, I want to start the presentation with a look at our revenue, EBITDA and net income after tax.

We'll start with a look at the quarter. As you can see, our sales were just below $4.8 million. That was a decline of 7% versus year ago, and this was impacted by a fair amount of trade loading and forward purchasing by our pharmaceutical customers in Canada, pharmacies and, in fact, patients. So the effect was strong accumulation and sales for us in first quarter, and it had a down effect on our revenue in April. We've seen -- subsequent to that, our business has smoothed out and the impact of a big March and a lower April has evened out, and we'll walk through that in a couple of slides.

So this represented our 40th consecutive profitable quarter, 10 years of continuous profitability. We

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot